Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

European Journal of Medical Research

M Ruhnke¹  G Kofla¹ 

[1] Charité University Medicine, Department of Medicine, Division of Oncology/Hematology, Charité Campus Mitte, Berlin, Germany

关键词: antifungal agents;    pharmacology;    micafungin;    caspofungin;    anidulafungin;    echinocandins;   

Others  :  825432
DOI  :  10.1186/2047-783X-16-4-159

 received in 2011-02-11, accepted in 2011-02-15,  发布年份 2011

【 摘 要 】

Echinocandins represent the newest class of antifungal agents. Currently, three echinocandins, anidulafungin, caspofungin and micafungin are licensed for clinical use in various indications. They act as inhibitors of β-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacological profile. They have a broad spectrum of activity against all Candida species. Higher MIC's have been observed against C. parapsilosis and C. guilliermondii. Data from clinical trials for invasive Candida infections/candidaemia suggest that the clinical outcome of patients treated with either drug may be very similar. A comparison has been done between caspofungin and micafungin but for anidulafungin a comparative trial with another echinocandin is still lacking. All three drugs are highly effective if not superior to treatment with either fluconazole or Amphotericin B, particularly in well-defined clinical settings such as invasive Candida infections, Candida oesophagitis and candidaemia. Differences between the three echinocandins with regard to the route of metabolism, requirement for a loading dose, dose adjustment in patients with moderate to severe hepatic disease and different dosing schedules for different types of Candida infections have to be considered. Relevant drug-drug interactions of Caspofungin and Micafungin are minimal. Anidulafungin has no significant drug interactions at all. However, echinocandins are available only for intravenous use. All three agents have an excellent safety profile.

【 授权许可】

   
2011 I. Holzapfel Publishers

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy 2007, 27(3):369-88.
• [2]Denning DW: Echinocandin antifungal drugs. Lancet 2003, 362(9390):1142-51.
• [3]Edmond MB, Wallace SE, McClish DK, et al.: Nosocomial bloodstream infections in United States hospitals: a three year analysis. Clin Infect Dis 1999, 29(2):239-44.
• [4]Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003, 36(9):1103-10.
• [5]Wisplinghoff H, Bischoff T, Tallent SM, et al.: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-17.
• [6]Pfaller MA, Diekema DJ, Jones RN, et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001, 39(9):3254-9.
• [7]Pfaller MA, Diekema DJ: Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004, 10(Suppl 1):11-23.
• [8]Pappas PG, Kauffman CA, Andes D, et al.: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-35.
• [9]Wiederhold NP, Lewis RE: The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003, 12(8):1313-33.
• [10]Odds FC, Brown AJ, Gow NA: Antifungal agents: mechanisms of action. Trends Microbiol 2003, 11(6):272-9.
• [11]Pound MW, Townsend ML, Drew RH: Echinocandin pharmacodynamics: review and clinical implications. J Antimicrob Chemother 2010, 65(6):1108-18.
• [12]European Medicines Agency: Anidulafungin. [http:/ / www.ema europa eu/ ema/ index jsp?curl=pages/ medicines/ human/ medicines/ 000788/ human_med_000751 jsp&murl=menus/ medicines/ medicinesjsp&mid=WC0b01ac058001d125] webcite 2009.
• [13]European Medicines Agency: Caspofungin. [http:/ / www.ema europa eu/ ema/ index jsp?curl=pages/ medicines/ human/ medicines/ 000379/ human_med_000684 jsp&murl=menus/ medicines/ medicines jsp&mid=WC0b01ac058001d12 5] webcite 2009.
• [14]European Medicines Agency: Micafungin. [http:/ / www.ema europa eu/ docs/ en_GB/ document_libra ry/ EPAR_ Product_Information/ human/ 000734/ WC500031075 pdf] webcite 2009.
• [15]Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34(3):857-63.
• [16]Chen SC, Slavin MA, Sorrell TC: Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011, 71(1):11-41.
• [17]Del PM, Cruz MC, Cardenas ME, et al.: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44(3):739-46.
• [18]Marchetti O, Moreillon P, Glauser MP, et al.: Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob Agents Chemother 2000, 44(9):2373-81.
• [19]Ostrosky-Zeichner L, Rex JH, Pappas PG, et al.: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47(10):3149-54.
• [20]Pfaller Ma, Diekema JJ, Ostrosky-Zeichner L, et al.: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46(8):2620-9.
• [21]Pfaller MA, Boyken L, Hollis RJ, et al.: In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveil-lance. J Clin Microbiol 2008, 46(1):150-6.
• [22]Clinical and Laboratory Standards Institute: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. Clinical and Laboratory Standards Institute 2008, 28(15):1-19.
• [23]Cheung C, Guo Y, Gialanella P, Feldmesser M: Development of candidemia on caspofungin therapy: a case report. Infection 2006, 34(6):345-8.
• [24]Miller CD, Lomaestro BW, Park S, Perlin DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006, 26(6):877-80.
• [25]Laverdiere M, Lalonde RG, Baril JG, et al.: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57(4):705-8.
• [26]Hernandez S, Lopez-Ribot JL, Najvar LK, et al.: Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004, 48(4):1382-3.
• [27]Moudgal V, Little T, Boikov D, Vazquez JA: Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005, 49(2):767-9.
• [28]Hakki M, Staab JF, Marr KA: Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006, 50(7):2522-4.
• [29]Kabbara N, Lacroix C, Peffault de LR, et al.: Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008, 93(4):639-40.
• [30]Balashov SV, Park S, Perlin DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50(6):2058-63.
• [31]Kahn JN, Garcia-Effron G, Hsu MJ, et al.: Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007, 51(5):1876-8.
• [32]Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al.: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003, 48(1):225-35.
• [33]Louie A, Deziel M, Liu W, et al.: Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005, 49(12):5058-68.
• [34]Petraitiene R, Petraitis V, Groll AH, et al.: Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1999, 43(9):2148-55.
• [35]Nguyen KT, Ta P, Hoang BT, et al.: Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob Agents Chemother 2009, 53(8):3347-52.
• [36]Cota J, Carden M, Graybill JR, et al.: In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006, 50(11):3926-8.
• [37]Gumbo T, Drusano GL, Liu W, et al.: Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007, 51(3):968-74.
• [38]Gumbo T, Drusano GL, Liu W, et al.: Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006, 50(11):3695-700.
• [39]Gumbo T: Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. Curr Opin Infect Dis 2007, 20(6):587-91.
• [40]Mehta PA, Vinks AA, Filipovich A, et al.: Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010, 16(10):1458-62.
• [41]Clemons KV, Espiritu M, Parmar R, Stevens DA: Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006, 50(4):1293-7.
• [42]Bizerra FC, Melo AS, Katchburian E, et al.: Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 2011, 55(1):302-10.
• [43]Melo AS, Colombo AL, Arthington-Skaggs BA: Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007, 51(9):3081-8.
• [44]Fleischhacker M, Radecke C, Schulz B, Ruhnke M: Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis 2008, 27(2):127-31.
• [45]Cateau E, Rodier MH, Imbert C: In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008, 62(1):153-5.
• [46]Cocuaud C, Rodier MH, Daniault G, Imbert C: Anti-metabolic activity of caspofungin against Candida albicans and Candida parapsilosis biofilms. J Antimicrob Chemother 2005, 56(3):507-12.
• [47]Kuhn DM, Ghannoum MA: Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 2004, 5(2):186-97.
• [48]Lattif AA, Mukherjee K, Chandra J, et al.: Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol 2009.
• [49]Weber K, Sohr R, Schulz B, et al.: Secretion of E, E-farnesol and biofilm formation in eight different Candida species. Antimicrob Agents Chemother 2008, 52(5):1859-61.
• [50]Onishi J, Meinz M, Thompson J, et al.: Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000, 44(2):368-77.
• [51]Gauthier GM, Nork TM, Prince R, Andes D: Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005, 41(3):e27-e28.
• [52]Hope WW, Mickiene D, Petraitis V, et al.: The Pharmacokinetics and Pharmacodynamics of Micafungin in Experimental Hematogenous Candida Meningoencephalitis: Implications for Echinocandin Therapy in Neonates. J Infect Dis 2008, 197(1):163-71.
• [53]Dowell JA, Stogniew M, Krause D, Damle B: Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007, 47(4):461-70.
• [54]Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 2006, 63(18):1693-703.
• [55]Estes KE, Penzak SR, Calis KA, Walsh TJ: Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy 2009, 29(1):17-30.
• [56]Hope WW, Smith PB, Arrieta A, et al.: Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010, 54(6):2633-7.
• [57]Gumbo T, Hiemenz J, Ma L, et al.: Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2007.
• [58]Nguyen TH, Hoppe-Tichy T, Geiss HK, et al.: Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007, 60(1):100-6.
• [59]Andes D, Pascual A, Marchetti O: Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53(1):24-34.
• [60]Betts RF, Nucci M, Talwar D, et al.: A Multicenter, doubleblind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009, 48(12):1676-84.
• [61]Cornely OA, Lasso M, Betts R, et al.: Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007, 60(2):363-9. Epub 2007 May 26
• [62]Stone JA, Holland SD, Wickersham PJ, et al.: Single -and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002, 46(3):739-45.
• [63]Walsh TJ, Adamson PC, Seibel NL, et al.: Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005, 49(11):4536-45.
• [64]van Burik JA, Ratanatharathorn V, Stepan DE, et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004, 39(10):1407-16.
• [65]Kuse ER, Chetchotisakd P, da Cunha CA, et al.: Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369(9572):1519-27.
• [66]de Wet N, Llanos-Cuentas A, Suleiman J, et al.: A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004, 39(6):842-9.
• [67]Damle B, Stogniew M, Dowell J: Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob Agents Chemother 2008, 52(7):2673-6.
• [68]Krause DS, Reinhardt J, Vazquez JA, et al.: Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004, 48(6):2021-4.
• [69]Krause DS, Simjee AE, van Rensburg C, et al.: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004, 39(6):770-5.
• [70]Hope WW, Seibel NL, Schwartz CL, et al.: Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007, 51(10):3714-9.
• [71]Benjamin DK Jr, Driscoll T, Seibel NL, et al.: Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006, 50(2):632-8.
• [72]Kartsonis NA, Nielsen J, Douglas CM: Caspofungin: the first in a new class of antifungal agents. Drug Resist Updat 2003, 6(4):197-218.
• [73]Saner F, Gensicke J, Rath P, et al.: Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006, 34(6):328-32.
• [74]Marr KA, Hachem R, Papanicolaou G, et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004, 6(3):110-6.
• [75]Steinbach WJ, Schell WA, Blankenship JR, et al.: In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob Agents Chemother 2004, 48(5):1664-9.
• [76]Walsh TJ, Teppler H, Donowitz GR, et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004, 351(14):1391-402.
• [77]Bruynesteyn K, Gant V, McKenzie C, et al.: A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol 2007, 78(6):532-9.
• [78]Cornely OA, Sidhu M, Odeyemi I, et al.: Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008, 24(6):1743-53.
• [79]Reboli AC, Rotstein C, Pappas PG, et al.: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356(24):2472-82.
• [80]Zilberberg MD, Kothari S, Shorr AF: Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009, 13(3):R94. BioMed Central Full Text